Pieris Pharmaceuticals, Inc.
PIRSNASDAQHealthcare
$13.60
$-2.51(-15.58%)
Market Cap$17955264
P/E Ratio—
52W High$22.32
52W Low$6.2
Pieris Pharmaceuticals, Inc. (PIRS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PIRS · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.04B | $0.03B | $0.03B |
| Cost of Revenue | $0.00B | $0.00B | $0.04B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.02B | $0.03B |
| Gross Margin %(computed) | — | — | 2.36% | 89.27% | 92.46% |
| Operating Expenses | |||||
| R&D Expenses | $0.02B | $0.01B | $0.04B | $0.05B | $0.07B |
| G&A Expenses | $0.02B | $0.01B | $0.02B | $0.02B | $0.02B |
| Total Operating Expenses | $0.04B | $0.01B | $0.07B | $0.06B | $0.08B |
| Operating Income | $0.00B | $0.00B | ($0.03B) | ($0.04B) | ($0.05B) |
| Operating Margin %(computed) | — | — | -69.51% | -167.84% | -164.97% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | ($0.01B) | ($0.00B) | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.04B) | ($0.02B) | ($0.02B) | ($0.03B) | ($0.05B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.04B) | ($0.02B) | ($0.02B) | ($0.03B) | ($0.04B) |
| Net Margin %(computed) | — | — | -57.33% | -120.66% | -138.03% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.71 | $-7.83 | $-21.80 | $-33.71 | $-53.75 |
| Wtd Avg Shares | 0.01B | 0.00B | 0.00B | 0.00B | 0.00B |
| EBITDA | $0.00B | $0.00B | ($0.02B) | ($0.03B) | ($0.05B) |
| EBITDA Margin %(computed) | — | — | -53.17% | -125.55% | -145.71% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Pieris Pharmaceuticals, Inc. data
About Pieris Pharmaceuticals, Inc. (PIRS) Income Statement
Pieris Pharmaceuticals, Inc. (PIRS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, PIRS reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.04B) — a net profit margin of —.
Frequently asked questions
PIRS · 4 questionsPieris Pharmaceuticals, Inc. (PIRS) reported revenue of $0.00B for 2025, down —% year-over-year.
PIRS revenuePIRS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09